{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients undergo radiotherapy once daily 5 days a week for up to 7 weeks.\n\nPatients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients receive oral dexamethasone on days 2-4. Patients with no emesis or need for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.\n\nPatients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion.\n\nfosaprepitant dimeglumine: Given IV\n\ncisplatin: Given IV\n\npalonosetron hydrochloride: Given IV\n\ndexamethasone: Given IV and orally\n\nFunctional Living Index-Emesis Questionnaire: Ancillary studies\n\nEmesis Diary: Ancillary studies\n\nRadiotherapy: Undergo r","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"25-120 hours following cisplatin infusion","title":"Rate of Complete Response to Anti-emetic Therapy in the Delayed Setting (25-120 Hours After Cisplatin Infusion)","type":"SECONDARY","unitOfMeasure":"Participants"}